Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Cash & Equivalents (2020 - 2026)

Climb Bio filings provide 7 years of Cash & Equivalents readings, the most recent being $8.4 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 71.21% to $8.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Mar 2026, down 71.21% year-over-year, with the annual reading at $35.7 million for FY2025, 59.09% down from the prior year.
  • Cash & Equivalents hit $8.4 million in Q1 2026 for Climb Bio, down from $35.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $223.1 million in Q2 2024 and bottomed at $8.4 million in Q1 2026.
  • Average Cash & Equivalents over 5 years is $92.7 million, with a median of $99.7 million recorded in 2023.
  • The largest annual shift saw Cash & Equivalents surged 274.05% in 2024 before it crashed 89.84% in 2025.
  • Climb Bio's Cash & Equivalents stood at $107.5 million in 2022, then fell by 13.35% to $93.1 million in 2023, then decreased by 6.32% to $87.2 million in 2024, then crashed by 59.09% to $35.7 million in 2025, then plummeted by 76.58% to $8.4 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Cash & Equivalents are $8.4 million (Q1 2026), $35.7 million (Q4 2025), and $25.8 million (Q3 2025).